Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas Biopharma Inc. is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections. Unlike standard intravenous amphotericin B, MAT2203 is formulated for once‐daily oral dosing and is intended to offer a lower toxicity profile. Matinas is also advancing MAT9001, an intravenous formulation of omega‐3 fatty acids for the management of severe hypertriglyceridemia, and MAT2501, an intravenous lipid‐based formulation of gentamicin for multidrug‐resistant bacterial infections.

Founded in 2012 and headquartered in Bedminster, New Jersey, Matinas Biopharma has designed its pipeline to address high‐unmet‐need areas in infectious disease and metabolic disorders. The company’s development programs have been conducted under U.S. Food and Drug Administration guidance, with clinical trials carried out at sites across North America. Matinas pursues strategic collaborations and licensing partnerships to broaden the application of its LNS technology to vaccines, oncology agents and biologics.

Matinas Biopharma completed its initial public offering in 2020 and trades on the New York Stock Exchange under the ticker symbol MTNB. The company’s management team brings together expertise in pharmaceutical R&D, regulatory affairs and commercial development, with the goal of translating its lipid‐delivery platform into safe, effective and convenient therapies for patients worldwide.

Key Stats

• Today's Range: $1.83 to $1.91
• 50-Day Range: $0.86 to $2.36
• 52-Week Range: $0.47 to $4.25
• Volume: 33,060 shs
• Average Volume: 58,104 shs
• Market Capitalization: $9.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Matinas Biopharma Stock Analysis - MarketRank™

Matinas Biopharma scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas Biopharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas Biopharma has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.63% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently decreased by 32.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas Biopharma does not currently pay a dividend.

Dividend Growth

Matinas Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.63% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently decreased by 32.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Matinas Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Matinas Biopharma is held by insiders.

Percentage Held by Institutions

Only 11.77% of the stock of Matinas Biopharma is held by institutions.

MTNB Stock Analysis - Frequently Asked Questions

How have MTNB shares performed this year?

Matinas Biopharma's stock was trading at $0.51 at the start of the year. Since then, MTNB stock has increased by 264.7% and is now trading at $1.86.

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02).

How do I buy shares of Matinas Biopharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Matinas Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include Acasti Pharma (ACST), SCYNEXIS (SCYX), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: N/A
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 30
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.25 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -210.21%
• Return on Assets: -138.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 4.07

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 8.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.49 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 5,090,000
• Free Float: 4,853,000
• Market Cap: $9.47 million
• Optionable: N/A
• Beta: 1.43